SCHEMBL6009609

SCHEMBL6009609

CCOC(=O)c1c(-c2cccc(Cl)c2)c2cc(C(O)c3nc(-c4ccccc4)cs3)ccc2[nH]c1=O

nearest known ligand 0.59

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CSF1R P07333 2/20 0.59
ALDH1A1 P00352 5/20 0.47
HPGD P15428 4/20 0.47
CYP1A2 P05177 2/20 0.47
CYP2C19 P33261 2/20 0.47
XBP1 P17861 1/20 0.47
ALOX5 P09917 4/20 0.45
L3MBTL1 Q9Y468 1/20 0.41
MAP3K5 Q99683 1/20 0.41
MEN1 O00255 4/20 0.41
KMT2A Q03164 4/20 0.41
SMN1; SMN2 Q16637 2/20 0.41
NPSR1 Q6W5P4 2/20 0.41
MAPT P10636 2/20 0.41
HSD17B10 Q99714 2/20 0.41
POLB P06746 1/20 0.41
TDP1 Q9NUW8 1/20 0.41
CYP2D6 P10635 1/20 0.41
CYP2C9 P11712 1/20 0.41
TSHR P16473 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6010149 0.92 CSF1R (0.59) CSF1RALDH1A1HPGDCYP1A2CYP2C19
SCHEMBL6009551 0.86 CSF1R (0.52) CSF1RALDH1A1HPGDCYP1A2CYP2C19
SCHEMBL6009493 0.83 CSF1R (0.61) CSF1RALDH1A1HPGDCYP1A2CYP2C19
SCHEMBL4849491 0.76 CSF1R (1.00) CSF1RALDH1A1HPGDCYP1A2CYP2C19
SCHEMBL6010479 0.71 FNTA (0.36) CSF1RALDH1A1HPGDMEN1KMT2A
SCHEMBL19952603 0.70 CSF1R (0.79) CSF1RALDH1A1HPGDCYP1A2CYP2C19
SCHEMBL29611931 0.70 CSF1R (0.79) CSF1RALDH1A1HPGDCYP1A2CYP2C19
SCHEMBL19952796 0.69 CSF1R (0.76) CSF1RALDH1A1HPGDCYP1A2CYP2C19
SCHEMBL29611904 0.69 CSF1R (0.76) CSF1RALDH1A1HPGDCYP1A2CYP2C19
SCHEMBL7818629 0.68 CSF1R (0.74) CSF1RALDH1A1HPGDCYP1A2CYP2C19

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7067531-B2 Farnesyl transferase inhibiting 6-heterocyclylmethyl quinolinone derivatives JANSSEN PHARMACEUTICA N.V. (BE) 2006-06-27 US disclosed
US-20030199547-A1 Farnesyl transferase inhibiting 6-heterocyclylmethyl quinolinone derivatives JANSSEN-CILAG S.A. (FR) 2003-10-23 US disclosed
EP-1322644-A1 FARNESYL TRANSFERASE INHIBITING 6-HETEROCYCLYLMETHYL QUINOLINONE DERIVATIVES JANSSEN PHARMACEUTICA N.V. (BE) 2003-07-02 EP disclosed
WO-2002024687-A1 FARNESYL TRANSFERASE INHIBITING 6-HETEROCYCLYLMETHYL QUINOLINONE DERIVATIVES JANSSEN PHARMACEUTICA N.V. (BE) 2002-03-28 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030199547-A1 Farnesyl transferase inhibiting 6-heterocyclylmethyl quinolinone derivatives FNTA, FNTB, RCE1 CSF1R 1793/4885ALDH1A1 645/4885HPGD 1635/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.